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For pre-clinical evaluation of biotherapeutic candidates, protein production by transient gene expression (TGE) 
in Chinese Hamster Ovary (CHO) cells offers important advantages, including the capability of rapidly 
generating recombinant proteins that are highly similar to those produced in stable CHO clones used for 
biomanufacturing. The higher cost of reagents necessary for TGE, specifically the requirement for large 
amounts of purified DNA and transfection agent for each production, means that improving the performance of 
CHO TGE could substantially augment the method’s utility. In the current study, we have established a novel 
CHO clone (CHO-3E7) expressing a form of the Epstein-Barr virus nuclear antigen-1 (EBNA-1). Transfection of 
EBNA-1-expressing cells with plasmid vectors encoding the Epstein-Barr virus OriP sequence boosted TGE 
productivity relative to parental CHO cells. Taking advantage of a new transfection-compatible media 
formulation that permits prolonged, high-density culture in shake flasks, we optimized transfection parameters 
(plasmid vector and polyethylenimine concentrations) and post-transfection culture conditions to establish a 
new, high-performing process for rapid protein production. The growth media is chemically defined, and a single 
hydrolysate feed is added at 24 h post-transfection, followed by periodic glucose supplementation. This method 
gave a maximum yield of 900 mg/L (for the chimeric IgG4 B72-3 mAb), with an average of 570 mg/L (standard 
deviation: 250 mg/L) for a panel of six mAbs and 320 mg/L (standard deviation: 140 mg/L) for five His-tagged 
recombinant proteins at 14 days post-transfection. Compared to our current low-density TGE process using 
CHO-3E7 cells and different culture medium, the new procedure gave on average 3-fold higher yields; purified 
mAbs produced using the two methods had distinct glycosylation profiles (by HILIC analysis) but showed 
identical target binding kinetics by SPR. Key advantages of the improved CHO-3E7-based protein production 
platform include the cost-effectiveness of the transfection reagent, the commercial availability of the culture 
media and the ability to perform high-cell-density transfection without media change.  
 
 
